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Early detection is crucial for achieving a reduction in breast cancer mortality. Analysis of circulating cell-free microRNAs present
in the serum of cancer patients has emerged as a promising new noninvasive biomarker for early detection of tumors and for
predicting their molecular classifications. The rationale for this study was to identify subtype-specific molecular profiles of cell-
free microRNAs for early detection of breast cancer in serum. Fifty-four early-stage breast cancers with 27 age-matched controls
were selected for circulating microRNAs evaluation in the serum. The 54 cases were molecularly classified (luminal A, luminal B,
luminal B Her2 positive, Her-2, triple negative). NanoString platform was used for digital detection and quantitation of 800 tagged
microRNA probes and comparing the overall differences in serum microRNA expression from breast cancer cases with controls.
We identified the 42 most significant (P ≤ 0.05, 1.5-fold) differentially expressed circulatingmicroRNAs in each molecular subtype
for further study. Of these microRNAs, 19 were significantly differentially expressed in patients presenting with luminal A, eight
in the luminal B, ten in luminal B HER 2 positive, and four in the HER2 enriched subtype. AUC is high with suitable sensitivity
and specificity. For the triple negative subtype miR-25-3p had the best accuracy. Predictive analysis of the mRNA targets suggests
they encode proteins involved in molecular pathways such as cell adhesion, migration, and proliferation. This study identified
subtype-specific molecular profiles of cell-free microRNAs suitable for early detection of breast cancer selected by comparison to
themicroRNAprofile in serum for female controls without apparent risk of breast cancer.Thismolecular profile should be validated
using larger cohort studies to confirm the potential of these miRNA for future use as early detection biomarkers that could avoid
unnecessary biopsy in patients with a suspicion of breast cancer.
1. Introduction
Breast cancer is the most common female cancer in the
world with an estimated 1.67 million new cases diagnosed
worldwide in 2012 [1]. Both clinically and biologically breast
cancer is a highly heterogeneous and guidelines provided
by AJCC 7th Edition Staging for Breast suggest using a
classification based on five molecular subtypes: luminal A,
luminal B, luminal B HER2 positive, HER2-enriched, and
triple negative [2]. The extent of disease at diagnosis is
strongly associated with prognosis, so that efficient and non-
invasive methods for early detection of initial stage disease
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Mammography is currently the best method for early
detection of breast cancer, but it has some limitations due to
the high number false positives and the unnecessary stress
that these diagnostic errors can cause [4, 5]. Biopsy repre-
sents the gold-standard procedure for definitive diagnosis,
although this procedure is invasive and may also be painful.
New multigene profiling panels for breast cancer are now
available, such as Oncotype DX (Genomic Healthy, USA)
MammaPrint (Agendia, Netherlands) and Prosigna/PAM50
(NanoString, USA); however, these assays are designed for
evaluating the risk of tumor recurrence and not suited for
early cancer detection [6]. In fact, there is a critical shortage
of noninvasive methods based on diagnostically sensitive
and specific breast cancer biomarkers suitable for both early
detection and subtype classification of tumors [7].
Liquid biopsies, such as blood samples, are less invasive
and easier to obtain compared to a tissue-based biopsy.
For a number of human tumors, including breast cancer,
biomarker analysis of circulating microRNAs (miRNA) from
serum is one of the most effective noninvasive for diagnoses
and evaluation of prognosis in different diseases [8]. The
extensive stability of miRNAs in peripheral blood and other
body fluids together with the relative ease of detection and
evaluation makes circulating miRNA ideal biomarkers to be
used as liquid biopsies [9]. Moreover, there is increasing
evidence that malignant mammary epithelial cells can release
miRNAs into peripheral blood so that themolecular profiling
of these miRNAs is an opportunity to develop new liquid
biopsies for early breast cancer detection and evaluation [10,
11]. Recently our group identified two circulating miRNAs as
potential tumor suppressors in invasive breast cancer [12].
In breast cancer, several miRNAs have already been
reported as potential biomarkers of metastasis, recurrence,
prognosis, or response to therapy [13, 14]. Examples include
miR-155 that is upregulated in breast cancer [15]. Another
study showed that circulating levels of miR-195 were elevated
in women with breast cancer (stage I-IV) in comparison to
healthy women [16]. However, at the present time, few studies
have found significantly altered miRNAs biomarkers that are
suitable for use in early diagnosis and detection of breast
cancer.
In this study, we applied multiplexed gene expression
analysis using nCounter Technology (NanoString Tech-
nologies, Seattle, WA, EUA) to identify miRNAs in liquid
biopsy samples from early-stage breast cancer patients. We
present analyses of 42 clinically relevant circulating, differen-
tially expressed miRNAs in the serum of 54 Brazilian breast
cancer patients. From these miRNAs, we selected a subset
of new biomarkers capable of distinguishing female breast
cancer patients from matched control of healthy women
without risk of this type of cancer.
2. Materials and Methods
2.1. Study Design and Patients. This is case-control study with
retrospective collection of biological samples and clinical
data. The early-stage (CS I and II) cases (n=54) were selected
from a bigger series of breast cancer patients diagnosed
at Barretos Cancer Hospital (BCH), having the following
features: age range 40-69 years old; no breast cancer recur-
rence; absence of family history/MIRIAD >10%; confirma-
tion of tumor stage and molecular subtype; and availability
of serum prior to chemotherapy or hormone therapy. Breast
cancer cases included were classified by molecular subtype
according to St. Gallen International Expert Consensus on
the Primary Therapy of Early Breast Cancer 2011.
The selected cases were matched to 27 controls by age (±
3 years). These controls were healthy women that underwent
mammography on the Prevention Department of BCH,
whose Gail Risk model was less than 1.66, mammography
result was BIRADS 1 or 2 and had blood collected.
All biological samples were retrieved from Barretos Can-
cer Hospital Tumor Biobank. This study was approved by
the Ethics Committee of Barretos Cancer Hospital (Protocol
n∘1212/2016), in accordance with the Declaration of Helsinki.
2.2. RNA Isolation from Serum Samples. Total RNA isolation
was recovered from 400uL of serum obtained from cases
and controls by miRNeasy Serum/Plasma Kit, including
RNase-Free DNase steps (Qiagen, Gaithersburg, MD, USA).
RNA quantification was performed using the NanoDrop N-
100 spectrophotometer (NannoDrop Products, Wilmington,
DE).
2.3. NanoString nCounter System Assays. The miRNA
expression analysis was performed using the nCounter
Human v3 miRNA Expression panel employing the nCoun-
ter Analysis System (NanoString Technologies, Seattle,
USA). Briefly, around 100 ng total RNA was preprocessed
Tags ligation followed by hybridization with the Reporter
CodeSet and Capture ProbeSet (nCounter Human v3
miRNAExpression Assay). Samples were processed using the
NanoString PrepStation and immobilized into the nCounter
cartridge, which was placed into the nCounter Digital
Analyzer for image capture (280 fields of view) and data
acquisition. Normalization was performed using standard
procedures established byMarkowitz et al., using the Aroma-
light package (Bioconductor) in R environment.
2.4. miRNA Target Prediction. Target prediction was per-
formed by miRDIP (microRNA Data Integration Portal:
http://ophid.utoronto.ca/mirDIP/). The target genes were
independently selected by five algorithms (DIANA, RNA22,
TargetScan, microrna.org, and RNAHybrid), using some
selection criteria of presence in at least four algorithms. We
only considered the top 1% of target genes, including those
that had already been identified by the Cancer Gene Index
data (NCI) as being involved in breast cancer. To further
determine how the selected genes were associated with breast
cancer and the molecular pathways that were related to
these genes, we used the plugin ReactomeFI on Cytoscape
(Version 3.6.0, Seattle, WA, USA). Molecular pathways were
selected considering p value lower than 0.01 and pathways
that included at least three genes. The interaction network
was performed by Cytoscape [13].
2.5. Statistical Analysis. Statistical analyses were performed
considering the normal distribution of samples. Student’s
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Luminal B HER2 positive 12 (22.2%)
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TNM classification of malignant tumors: T describes the tumor size of
primary tumor; N describes regional lymph nodes that are involved; M
describes distant metastasis.
t-test was performed, using the Bioconductor multtest pack-
age. Fold-change estimation, area under (AUC) the Oper-
ating Characteristic Curve (ROC), sensitivity and speci-
ficity analysis were performed to determine the accuracy of
differentially expressed miRNAs. The ROC curve analysis
was performed using the ROCR package (Bioconductor) in
R program. All images resulting from this analysis were
generated from the ggplot2 and ComplexHeatmaps packages
(Bioconductor).
3. Results
3.1. Study Population. The clinicopathological features of
the 54 patients with early-stage breast cancer (cases) are
summarized in Table 1. The median age of early-stage breast
cancer cases was 54.6 years old (range 41-69 years). The
control group (n=27) wasmatched with the early-stage breast
cancer cases by age (± 3 years) and the median age was 54.3
years old (range 42-67 years).
3.2. Identification of Differentially Expressed miRNAs in Breast
Cancer Cases. All cases were stratified according clinical
stage I and II and by molecular subtypes (luminal A, luminal
B, luminal B Her2 positive, Her-2, and triple negative). This
stratification was employed for specifically distinguishing
miRNAs biomarkers from the cases and controls for early
detection of breast cancer.
Of the 800 miRNAs determined by NanoString Tech-
nology, 21 had significant differential expression (P ≤ 0.05,
1.5-fold) in the luminal A subtype comprising 11 miRNAs that
were downregulated and 10 miRNA that were upregulated in
serum of breast cancer cases in comparison with serum from
the matched healthy controls (Figure 1).
For luminal B subtype, 11 miRNAs had significant differ-
ential expression (P≤ 0.05, 1.5-fold), including 6miRNAs that
were downregulated and 5 miRNAs that were upregulated in
serum of cases with breast cancer in comparison with the
matched healthy controls (Figure 2).
For luminal B HER2 positive subtype, 12 miRNAs had
significant differential expression (P ≤ 0.05, 1.5-fold), includ-
ing 8 miRNAs that were downregulated and 4 miRNAs that
were upregulated in serum of cases with breast cancer in
comparison with matched healthy controls (Figure 3).
For HER 2-enriched subtype, 4 miRNAs had significant
differential expression (P ≤ 0.05, 1.5-fold), including 3 miR-
NAs that were downregulated and one miRNA that was
upregulated in serum of breast cancer cases compared with
matched healthy controls (Figure 4).
For triple negative subtype, only miR-25-3p was upreg-
ulated (P ≤ 0.05, 1.5-fold) in serum of the cases with
breast cancer in comparison with matched healthy controls
(Figure 5).
3.3. Evaluation of Circulating miRNAs as Biomarkers for
Breast Cancer Subtypes. To evaluate the accuracy of the
miRNAs as biomarkers for detection of breast cancer in
serum, we determined the Receiver Operating Characteristic
(ROC) curves, sensitivity and specificity of each miRNA. We
considered an area under the ROC curve (AUC) ≥ 0.8 as a
cutoff for further investigation and we identified 36 out of 42
differentially miRNAs as suitable biomarkers in the subtypes
luminal A, luminal B, luminal B HER-2 positive and HER2-
enriched (Table 2). For triple negative, miR-25-3p showed a
slightly low AUC of 0.74.
Among these 36 miRNAs, 21 were downregulated and
16 were upregulated with miR-615-3p being upregulated in
luminal BHER 2 positive cases, but also being downregulated
in HER2-enriched tumors (Figures 6 and 7). The subtype
specificity of the 42 circulating miRNAs (Table 2) showed
that 19 miRNAs were significantly differentially expressed
in patients presenting with luminal A molecular subtype, 8
miRNAs in patients presenting with luminal B subtype, 10
miRNAs in patients presentingwith luminal BHER 2 positive
subtype, 4miRNAs in patients presenting with the subtype in
HER2-enriched, and only one miRNA in the triple negative
subtype.
3.4. Functional In Silico Analysis. In order to identify the
potential target mRNAs of the differentially expressed miR-
NAs, we identified the top increased (miR-25-3p, Fold change
3,56) and top decreased (miR-378d, Fold change: -2,65)
miRNAs in each of the five molecular subtypes of breast
cancer (Figure 8).
We identified the target genes for miR-378d and miR-25-
3p using the online prediction tool miRDIP. We were unable
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Figure 1: miRNAs differentially expressed in serum samples of patients with luminal A breast cancer. Heatmap demonstrating the
differentially expressed miRNAs found in the serum of luminal A breast cancer patients compared with healthy women.
Figure 2: miRNAs differentially expressed in serum samples of patients with luminal B breast cancer. Heatmap demonstrating the
differentially expressed miRNAs found in the serum of luminal B breast cancer patients compared with healthy women.
Journal of Oncology 5
Figure 3: miRNAs differentially expressed in serum samples of patients with luminal BHER2 positive breast cancer. Heatmap demonstrating
the differentially expressed miRNAs found in the serum of luminal B HER 2 positive breast cancer patients compared with healthy women.
Figure 4: miRNAs differentially expressed in serum samples of patients with HER2-enriched breast cancer. Heatmap demonstrating the
differentially expressed miRNAs found in the serum of HER2-enriched breast cancer patients compared with healthy women.
to identify target genes predicted for miR-378d, but there
were 14 target genes predicted for miR-25-3p.
Among these miR-25-3p predicted target genes, we found
four molecular pathways (Integrin signalling pathway, EPHB
forward signalling, FoxO signalling pathway and Ras sig-
nalling pathway) that had statistical significance for the
regulation of cell adhesion, migration, and proliferation.
These molecular pathways also overlap with the target gene
NRAS see Figure S1 in the Supplementary Material for
comprehensive image analysis).
4. Discussion
Mammographic screening is the gold-standard tool for the
detection of early breast cancer lesions, yet it has several
limitations such as false positive results and it is not very
well accepted by all women since it is a very uncomfortable
approach [17, 18]. In addition, breast cancer is classified in
different histological and molecular subtypes, which present
distinctive degrees of aggressiveness [17, 18]. Currently, only
tissue samples obtained from conventional biopsy procedure
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Figure 5: miRNAs differentially expressed in serum samples of patients with triple negative breast cancer. Heatmap demonstrating the
differentially expressed miRNAs found in the serum of triple negative breast cancer patients compared with healthy women.
Figure 6: Venn diagram of downregulated miRNAs in serum of breast cancer patients. Venn diagram demonstrating 21 downregulated
miRNAs, including miR-887-5p common between luminal A and luminal B HER2 positive. (a) HER 2; (b) luminal A; (c) luminal B; (d)
luminal B HER2 positive.
can be useful for histological and molecular classification of
this type of tumor.Thus, the liquid biopsy approach for breast
cancer screening could improve the mammography sensi-
tivity and could also be helpful for molecular classification
[19, 20].
The miRNAs have attracted a great deal of attention
as cancer biomarkers in the last few years due to the
possibility of their detection from plasma or blood serum
using conventionalmethods that could be adapted to clinical-
laboratory routine [21, 22]. In addition, these circulating
miRNAs have already been associated with the presence of
various types of cancer [23, 24]. We therefore hypothesized
that the identification of tumor-specific circulating miRNAs
could be used for early detection of breast cancer as well
as molecular biomarkers for identification of the different
subtypes of breast cancer.
Most of minimally invasive biomarkers already described
for breast cancer present low accuracy. A good example of
minimally invasive biomarker for breast cancer is the CA 125,
a serum biomarker that demonstrates 69% specificity and
8 Journal of Oncology
Figure 7: Venn diagram of upregulated miRNAs in serum of breast cancer patients. Venn diagram demonstrating 16 upregulated miRNAs,
including miR-548ah-5p common between luminal A and luminal B, miR-548ar-5p common between HER2 and luminal B, and miR25-3p
common between luminal A and luminal B HER 2 positive. (a) HER 2; (b) luminal A; (c) luminal B; (d) luminal B HER2 positive.
only 23% sensitivity [25]. Other serum biomarkers such as
CEA and CA 15-3 are only reported to be effective in less than
15% of breast cancer patients [26].
An important finding of our study was that miR-25-3p
could distinguish patients with triple negative breast cancer
(themost aggressive subtype) from healthy controls. MiR-25-
3p was also found to be upregulated in triple negative breast
cancer tissue and cell lines [27]. Our prediction analyses
showed that BTG2 is a putative target of miR-25-3p, so it
seems possible that this miRNA may promote proliferation
by targeting BTG2 in triple negative breast cancer. We found
that miRNAs are important biomarkers for prognosis in
triple negative breast cancer. For example, downregulated
miR-221-3p is associated with poor prognostic biomarker
for triple negative breast cancer [28]. However, few studies
have been performed for early diagnosis using triple negative
breast cancer because most cases of this aggressive molecular
subtype are detected at an advanced stage.
In our study, it is possible that experimental variables due
to sampling influenced the comparison between the 12 triple
negative cases and the healthy controls. Also, the clinical and
biological behavior of the triple negative molecular subtype
is known to be more heterogeneous in comparison to the
hormone receptor groups (luminal A, luminal B, luminal B
HER 2 positive and HER2-enriched), which we were able
to distinguish based on miRNA expression. Although the
accuracy of the circulating miRNAs identified in HER2-
enriched molecular subtype in our study was excellent, we
believe it is necessary to validate these miRNAs using a larger
cohort to increase the statistical power since only six patients
were available for our analysis.
Considering that this study is retrospective, we have few
serum breast cancer samples without any treatment available
and small control group that Gail’s Risk is determined. Thus,
larger prospective studies are required to define the most
robust circulating miRNA signature for improved clinical
management of breast cancer usingminimally invasive meth-
ods that avoid unnecessary biopsies. More extensive studies
are needed to discover whether miR-25-3p could be a specific
early detection biomarker for triple negative breast cancer.
5. Conclusions
Thus, in this case-control study we identified a molecu-
lar signature miRNAs as noninvasive biomarkers for each









































































Figure 8: Differentially expressed miRNAs by molecular subtype breast cancer. Volcano plot demonstrating the profile of the differentially
expressed miRNAs in different molecular subtypes of breast cancer. This plot demonstrates the fold change (x-axis) and the − log 10 P value
(y-axis). The green circles represent the miRNAs downregulated and the red circles represent the miRNAs upregulated. The black circles
indicate miRNAs that were not significantly expressed. Significance was determined with a P value cutoff of 0.05 and a 1.5-fold change.
Molecular subtypes in breast cancer analyzed: (a) luminal A – arrow indicates the top upregulated miRNA (miR-25-3p); (b) luminal B; (c)
luminal B HER 2 positive – arrow indicates the top downregulated miRNA (miR-378d); (d) HER2-enriched; (e) triple negative.
10 Journal of Oncology
molecular subtype (luminal A, luminal B, luminal B HER2
positive andHER2-enriched breast) with increased precision.
Future studies will be required to validate the clinical utility of
these miRNAs using larger cohorts. Collectively our findings
show that independently miRNAs can be detected in serum
from patients with early breast cancer and their differen-
tial expression may be associated with specific molecular
subtypes. Thus, the liquid biopsy approach using molecular
biomarkers can be employed in the routine of breast cancer
screening with potential to decrease the unnecessary invasive
procedure.
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